Czibere Akos 4

What Happened

• Akos Czibere, Chief Medical Officer of Aktis Oncology (AKTS), exercised 50,000 option shares at $4.95 per share (cost $247,500) on July 8, 2026, and sold a total of 50,000 common shares in open-market transactions the same day for aggregate proceeds of $1,388,701.
• The open‑market sales were reported as three separate blocks: 14,800 shares at a weighted average $27.13 ($401,484), 30,829 shares at $27.95 ($861,735), and 4,371 shares at $28.71 ($125,482). The Form 4 also lists a derivative disposition of 50,000 shares at $0.00 (reported as code M).

Key Details

• Transaction date: July 8, 2026; Form 4 filed July 10, 2026 (timely filing).
• Exercise acquired: 50,000 shares @ $4.95 = $247,500.
• Market sales: total 50,000 shares for $1,388,701 (three blocks; weighted avg prices shown above). Price ranges per footnotes: 26.52–27.51; 27.53–28.50; 28.63–28.74.
• Additional derivative line: 50,000 shares reported disposed at $0.00 (as reported; filing does not detail the economic nature of that entry).
• Shares owned after transaction: not specified in the provided excerpt.
• Vesting note: Footnote F4 shows the option vests 25% on July 1, 2025, then 1/48 monthly thereafter (continuous service required).

Context

• Code M indicates exercise/conversion of a derivative (options). The filing shows an exercise and contemporaneous market sales — commonly seen when insiders exercise options and sell shares to cover exercise cost, taxes, or for diversification; the filing itself does not state the insider’s motivation.
• The separate derivative disposition at $0.00 may reflect a net/withholding settlement or other internal accounting treatment; the filer or issuer can provide full details on request.
• This is routine insider trading information (not a 10% owner disclosure) and was filed within the normal 2-business-day window.